Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Instil BioTIL -1.25%31 EV-to-FCF is -1.76 as of Jul. 26, 2026. GuruFocus rates TIL with a GF Score™ of 31/100. The stock has 3 warning signs investors should review. Among 343 Biotechnology companies, Instil Bio ranks worse than 291544.9% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Instil Bio's Enterprise Value is $59.44 Mil.
Instil Bio's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-33.76 Mil. Therefore, Instil Bio's EV-to-FCF for today is -1.76.
The historical rank and industry rank for Instil Bio's EV-to-FCF or its related term are showing as below:
TIL'
s EV-to-FCF Range Over the Past 10 Years
Min: -38.62 Med: 3.19 Max: 3.71
Current: -1.76
During the past 7 years, the highest EV-to-FCF of Instil Bio was 3.71. The lowest was -38.62. And the median was 3.19.
TIL's EV-to-FCF is ranked worse than 100% of 343
companies
in the Biotechnology industry
Industry Median: 14.7
vs TIL: -1.76
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Instil Bio's share price for today is $7.20.
Instil Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.040.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Instil Bio EV-to-FCF Related Terms
Instil Bio EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Instil Bio's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Instil Bio's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Instil Bio EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Instil Bio's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Instil Bio's EV-to-FCF falls into.
Instil Bio's current Enterprise Value is $59.44 Mil.
Instil Bio's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-33.76 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Instil Bio (TIL) has a EV-to-FCF of -1.76 as of Jul. 26, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Instil Bio and its competitors. According to the industry distribution chart, Instil Bio ranks #999999 out of 343 companies in the Biotechnology industry.
Is Instil Bio's EV-to-FCF too high?
Instil Bio's current EV-to-FCF is -1.76. Based on the distribution chart, Instil Bio ranks #999999 out of 343 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Instil Bio has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Instil Bio's EV-to-FCF compare to AURX and MCRB?
According to the Biotechnology industry distribution chart, Instil Bio ranks #999999 out of 343 companies for EV-to-FCF. This places Instil Bio in the lower half of its industry. The industry median EV-to-FCF is 14.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.70, based on 343 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Instil Bio and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Instil Bio's current EV-to-FCF is -1.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Instil Bio stock overvalued right now?
Instil Bio (TIL) has a current EV-to-FCF of -1.76. The current EV-to-FCF is -1.76. Instil Bio's overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Instil Bio (TIL), the current EV-to-FCF is -1.76 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
31GF Score
Get the complete analysis for TIL
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TIL has been successfully added to your 
